Heyman Richard A.'s Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Jan 12, 2026
- Accession no.
- 0001584759-26-000004
- Filed
- Jan 12, 2026
- Trade date
- Jan 8-9, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $348.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Heyman Richard A.CIK 0001584759 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 8, 2026 | Common Stock | SSaleDisposed | −1,620 | $25.00 | −$40,500 | 25,545 | Indirect | |
| Jan 8, 2026 | Common Stock | SSaleDisposed | −8,015 | $25.04 | −$200,695.6 | 29,392 | Indirect | |
| Jan 9, 2026 | Common Stock | SSaleDisposed | −4,285 | $25.00 | −$107,125 | 25,107 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.